Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
<p>(A-D) YUO-006 and YUO-010 (Patient-derived organoids), YU-1089 and YU-1095 (Patient-derived cells) or HCC827-AR and H820 (ATCC cell lines) were seeded on a 96-well plate and incubated with the MET TKIs (tepotinib) and EGFR TKIs (osimertinib or gefitinib) for 3 days. EGFR TKIs was treated wi...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , , , , , , , , , , , |
| Veröffentlicht: |
2025
|
| Schlagworte: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1849927634218123264 |
|---|---|
| author | Seung Yeon Oh (15051017) |
| author2 | You Won Lee (15051020) Eun Ji Lee (15051023) Jae Hwan Kim (15051026) YoungJoon Park (15051029) Seong Gu Heo (15032490) Mi Ra Yu (15051032) Min Hee Hong (15014541) John DaSilva (15051035) Christopher Daly (15030374) Byoung Chul Cho (15032496) Sun Min Lim (15051038) Mi Ran Yun (15032484) |
| author2_role | author author author author author author author author author author author author |
| author_facet | Seung Yeon Oh (15051017) You Won Lee (15051020) Eun Ji Lee (15051023) Jae Hwan Kim (15051026) YoungJoon Park (15051029) Seong Gu Heo (15032490) Mi Ra Yu (15051032) Min Hee Hong (15014541) John DaSilva (15051035) Christopher Daly (15030374) Byoung Chul Cho (15032496) Sun Min Lim (15051038) Mi Ran Yun (15032484) |
| author_role | author |
| dc.creator.none.fl_str_mv | Seung Yeon Oh (15051017) You Won Lee (15051020) Eun Ji Lee (15051023) Jae Hwan Kim (15051026) YoungJoon Park (15051029) Seong Gu Heo (15032490) Mi Ra Yu (15051032) Min Hee Hong (15014541) John DaSilva (15051035) Christopher Daly (15030374) Byoung Chul Cho (15032496) Sun Min Lim (15051038) Mi Ran Yun (15032484) |
| dc.date.none.fl_str_mv | 2025-11-25T12:44:03Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30706008 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplementary_Figure_4_from_Preclinical_Study_of_a_Biparatopic_METxMET_Antibody_Drug_Conjugate_REGN5093-M114_Overcomes_MET-driven_Acquired_Resistance_to_EGFR_TKIs_in_EGFR-mutant_NSCLC/30706008 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Therapeutic Research and Development Drug Resistance Clinical drug resistance Lung Cancer Translational Research |
| dc.title.none.fl_str_mv | Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>(A-D) YUO-006 and YUO-010 (Patient-derived organoids), YU-1089 and YU-1095 (Patient-derived cells) or HCC827-AR and H820 (ATCC cell lines) were seeded on a 96-well plate and incubated with the MET TKIs (tepotinib) and EGFR TKIs (osimertinib or gefitinib) for 3 days. EGFR TKIs was treated with concentration of 0nM, 30nM, 100nM. MET TKIs, tepotinib were treated with serial concentrations from 0nM to 100nM. The bar-graphs show the cell viability for the combination of two drugs, and the curved graphs show the cell viability results for a single drug.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_cac83cd93869eb7a7636628c31f00379 |
| identifier_str_mv | 10.1158/1078-0432.30706008 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30706008 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLCSeung Yeon Oh (15051017)You Won Lee (15051020)Eun Ji Lee (15051023)Jae Hwan Kim (15051026)YoungJoon Park (15051029)Seong Gu Heo (15032490)Mi Ra Yu (15051032)Min Hee Hong (15014541)John DaSilva (15051035)Christopher Daly (15030374)Byoung Chul Cho (15032496)Sun Min Lim (15051038)Mi Ran Yun (15032484)CancerTherapeutic Research and DevelopmentDrug ResistanceClinical drug resistanceLung CancerTranslational Research<p>(A-D) YUO-006 and YUO-010 (Patient-derived organoids), YU-1089 and YU-1095 (Patient-derived cells) or HCC827-AR and H820 (ATCC cell lines) were seeded on a 96-well plate and incubated with the MET TKIs (tepotinib) and EGFR TKIs (osimertinib or gefitinib) for 3 days. EGFR TKIs was treated with concentration of 0nM, 30nM, 100nM. MET TKIs, tepotinib were treated with serial concentrations from 0nM to 100nM. The bar-graphs show the cell viability for the combination of two drugs, and the curved graphs show the cell viability results for a single drug.</p>2025-11-25T12:44:03ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30706008https://figshare.com/articles/figure/Supplementary_Figure_4_from_Preclinical_Study_of_a_Biparatopic_METxMET_Antibody_Drug_Conjugate_REGN5093-M114_Overcomes_MET-driven_Acquired_Resistance_to_EGFR_TKIs_in_EGFR-mutant_NSCLC/30706008CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307060082025-11-25T12:44:03Z |
| spellingShingle | Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC Seung Yeon Oh (15051017) Cancer Therapeutic Research and Development Drug Resistance Clinical drug resistance Lung Cancer Translational Research |
| status_str | publishedVersion |
| title | Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC |
| title_full | Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC |
| title_fullStr | Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC |
| title_full_unstemmed | Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC |
| title_short | Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC |
| title_sort | Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC |
| topic | Cancer Therapeutic Research and Development Drug Resistance Clinical drug resistance Lung Cancer Translational Research |